% | $
Quotes you view appear here for quick access.

Gilead Sciences Inc. Message Board

  • peter_norths_proctologist peter_norths_proctologist Jun 3, 2013 6:34 PM Flag

    Barrons says the news from ASCO isn't bright for Gilead, Onyx, and BioMarin

    Quote from Barrons:

    "Drug stocks have had a good year so far amid growing excitement over pipelines that are ripe with exciting new drugs. The Nasdaq Biotech Index has jumped 31% since the start of the year. And the NYSE ARCA Pharmaceutical Index has climbed a more sedate 14%.

    But for some stocks, the news from ASCO isn’t bright.

    BioMarin Pharmaceuticals (BMRN) slumped 7.8% to $57.78 after the company reported Monday morning that its experimental drug BMN 673 meaningfully shrank the tumors of less than half of the breast and ovarian cancer patients on which it was tested.

    Shares of Onyx Pharmaceuticals (ONXX) shrank 6.5% to $89.24 after its drug Nexavar helped to stall the growth of a rare type of advance thyroid cancer but made no difference in patients’ overall survival. So that could hurt the drug’s commercial opportunity, according to Barclays Capital analyst Ying Huang.

    And after presenting data on its experimental leukemia drug, Gilead Sciences (GILD) fell 3.1% to $52.77."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Yes, that's posted a basic blog update posted everywhere on the internet.
      I'm sorry, are you dyslexic?
      Where do you see the word "bad" data?

      Let's take a look at today's movement at the major players who presented at ASCO to date. SHALL WE?

      Biogen Idec Inc. (BIIB) -NasdaqGS
      227.39 - 10.10(4.25%)
      Celgene Corporation (CELG) -NasdaqGS
      120.89 - 2.76 (2.23%)
      ALXN Alexion Pharmaceuticals, Inc
      - 2.10 (2.15%)

      Any half wit could see this move is about basic market conditions and a healthy rotation, than it is a retreat. Your terrified, or you wouldn't be trying this hard patrolling a board for months trying to scare pennies out of a retail clients. What's more pathetic, is you have little thought of the company your bashing, the industry, or it's possible benefit to your wormy existence. Why don't you get a job stocking shelves in RiteAid, where you can be around pharmaceuticals, learn something about the industry, and make enough $ to get out of mom's basement! That way you won't have to bash a company you know little about.

100.69-0.31(-0.31%)Mar 30 4:00 PMEDT